IFUAF

ARNOLD & PORTER LLP

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206



July 6, 2004

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: 1634

Examiner: M.B. Sheinberg

Conf. No.: 1690

Re: U.S. Patent Application Serial No. 09/955,216 filed September 19, 2001

Inventors: Sherri M. BROWN et al.

Title: Nucleic Acid Molecules and Other Molecules Associated

with the Gibberellin Pathway

Atty. Dkt: 16517.257

Sir:

Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

- 1. Amendment After Final Rejection; and
- 2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any additional fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing docket number 16517.257. A duplicate copy of this letter is enclosed.

Sincerely,

David R. Marsh (Reg. No. 41,408)

Enclosures

In re application of:

Sherri M. BROWN et al.

Appln. No.: 09/955,216

Filed:

September 19, 2001

Title:

Nucleic Acid Molecules and

Other Molecules Associated with

the Gibberellin Pathway

Art Unit:

1634

Examiner:

Monika B. SHEINBERG

Atty. Docket:

16517.257

Confirm. No.:

1690

AMENDMENT AFTER FINAL REJECTION

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Final Office Action mailed May 5, 2004 ("Final Action"), Applicants submit the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.